Liver Cancer News and Research

RSS
Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.
Vodka contributes to high death rates in Russia, new study confirms

Vodka contributes to high death rates in Russia, new study confirms

Researchers find liver tumors in mice exposed to BPA during gestation and nursing

Researchers find liver tumors in mice exposed to BPA during gestation and nursing

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

Researchers identify potential genes that can be targeted for new treatments for hepatocellular cancer

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

New pre-clinical data shows potential protective effects of GFT505 in different types of cancer

Surgeon general: Smoking linked to more than 30 diseases, conditions

Surgeon general: Smoking linked to more than 30 diseases, conditions

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

Gilead Sciences gets marketing authorization from European Commission for Sovaldi 400 mg tablets

First Edition: January 17, 2014

First Edition: January 17, 2014

Monitoring individuals with chronic HBV is cost-effective strategy for China

Monitoring individuals with chronic HBV is cost-effective strategy for China

New drug combination proves effective in treatment of hepatitis C

New drug combination proves effective in treatment of hepatitis C

Research: SLPI protein produced by body in response to injury plays vital role in patients with ALF

Research: SLPI protein produced by body in response to injury plays vital role in patients with ALF

Blueprint Medicines closes $25 million Series B financing

Blueprint Medicines closes $25 million Series B financing

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Marina Biotech, Mirna modify license agreement regarding development of microRNA-based therapeutics

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Researchers identify molecular link between liver cancer, obesity, alcoholism, and hepatitis

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Cellular Biomedicine Group completes TC-DC Phase I clinical trial for hepatocellular carcinoma

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

Circulating nucleosomes and colorectal cancer diagnostics: an interview with Dr. Stefan Holdenrieder, University Hospital Bonn

HCV antiviral therapy also improves diabetes outcomes

HCV antiviral therapy also improves diabetes outcomes

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Genetic deficiency in males can trigger hepatocellular carcinoma, type 2 diabetes

Revised Clinical Practice Guidelines on management of HCV published by EASL

Revised Clinical Practice Guidelines on management of HCV published by EASL

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Study: Ethnic groups with high prevalence of diabetes have high hepatocellular carcinoma rates

Transgene welcomes SillaJen’s intention to acquire Jennerex

Transgene welcomes SillaJen’s intention to acquire Jennerex

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.